Pfizer

Pfizer has purchased a controlling stake in Redvax, a spin-off from Swiss biopharmaceutical firm Redbiotec.

Terms of the transaction were not disclosed.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Redvax is a preclinical stage company, which develops multi-component virus-like particles (VLPs) and other protein assemblies for vaccine development in the field of cytomegalovirus (CMV) and a further undisclosed field.

Pfizer senior vice-president of vaccine research and early development Kathrin Jansen said: "Through the acquisition of the Redvax innovative CMV vaccine platform and expertise, we will seek to develop a vaccine to prevent a difficult disease that can have a devastating and lifelong impact on young children."

"The deal allows Pfizer to gain access to a preclinical human CMV vaccine candidate, in addition to intellectual property and a technology platform related to a second, undisclosed vaccine programme."

The deal allows Pfizer to gain access to a preclinical human CMV vaccine candidate, in addition to intellectual property and a technology platform related to a second, undisclosed vaccine programme.

See Also:

The CMV vaccine programme is said to be in line with Pfizer’s portfolio of investigational vaccines, while CMV is a herpes virus, infecting 50%-90% of the adult population, with a majority remaining asymptomatic.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Redbiotec CEO and Redvax managing director Christian Schaub said: "We are pleased to have completed this deal with Pfizer, a global leader in vaccines.

"This represents an important step toward the development of a much needed vaccine for CMV, a disease that has a devastating impact on children and families."

According to US Centres for Disease Control and Prevention (CDC), 5,000 children each year develop health problems caused by CMV such as hearing or vision loss and mental disability.

Image: Pfizer World Headquarters. Photo: courtesy of Norbert Nagel, Mörfelden-Walldorf, Germany.